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ABSTRACT 
Approximately 2% of the US population is affected by chronic migraine (CM). CM is a 
recurring, neurological disorder characterized by painful headache, along with 
autonomic, gastrointestinal, and other somatic symptoms.  Prolonged sensitization of the 
trigeminal system, which is implicated in CM, is comprised of peripheral primary 
trigeminal ganglion neurons that provide sensory innervation of the head and face and 
second order neurons in the spinal trigeminal nucleus (STN). The goal of my study was 
to evaluate anti-migraine drugs for their ability to inhibit ongoing peripheral and central 
sensitization of trigeminal nociceptors. An in vivo animal model was used to determine if 
two novel drugs in development and Topiramate, a common drug used to treat frequent 
migraine, could inhibit nocifensive responses to mechanical stimulation of trigeminal 
neurons.  In addition, the trigeminal ganglion and STN were evaluated on a molecular 
level to determine if the drugs could inhibit expression of a signaling protein implicated 
in peripheral and central sensitization. My results provide evidence that the two novel 
drugs significantly inhibited nocifensive responses and decreased expression of Protein 
Kinase A (PKA) in the trigeminal ganglion and STN. In contrast, Topiramate did not 
decrease PKA expression and had no effect on nocifensive responses. Based on my 
findings, I conclude that these novel drugs may be beneficial in the treatment of CM.   
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1 
INTRODUCTION 
 
Chronic Migraine 
Worldwide, primary headache disorders are the most common neurological 
condition for which medical consultation is sought (Stovner et al., 2007). In the United 
States alone, approximately 12% of the adult population suffers from migraine with and 
without aura (Stewart et al., 2003, Lipton et al., 2007). The most common symptoms of a 
migraine attack include a throbbing headache that can last up to 72 hours, increased 
sensitivity to light (photophobia) and noise (phonophobia), nausea (feeling sick), 
vomiting (being sick) and lethargy (lack of energy).  Some migraineurs experience 
neurological symptoms that are referred to as migraine aura in which they “see” dark or 
colored spots, sparkles or ‘stars’, or zigzag lines prior to headache onset.  In addition, 
migraine attacks can be preceded by a feeling of numbness or tingling, weakness, and 
dizziness or vertigo, disturbances in speech and hearing, and even reported memory 
changes such as feelings of fear and confusion.   Migraine attacks can be further 
subdivided into two major categories: episodic and chronic (Manack et al., 2011).  
Although chronic migraine was once thought of as an extension of episodic migraine, 
recent studies have shown that this is not the case.  Acute pain, which is a result of 
episodic migraines, has been described as transient, self-limiting, and serves a protective 
biological function.  In contrast, chronic pain can cause long-term maladaptive changes in 
neuroplastic tissues, is not believed to serve a protective biological function, and can 
become detrimental to one’s overall health by promoting other illnesses (Schulman et al., 
2008).  
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Chronic migraine ranks among the eight most burdensome conditions according 
to the Global Burden of Disease of the World Health Organization (WHO) (Vos et al., 
2012).  Due to the debilitating nature of migraine, the WHO has considered a day with 
chronic migraine comparable to a day with quadriplegia or severe psychosis (Menken et 
al., 2000).  Interestingly, chronic migraine has only recently been classified as its own 
disorder.  The International Headache Society (IHS) included the diagnosis of chronic 
migraine for the first time in 2004, and appended the definition in 2006 to define chronic 
migraine as 15 or more “headache days” a month for 3 or more consecutive months, with 
8 or more of those headache days fulfilling the IHS criteria for migraine (Headache 
Classification Subcommittee of the International Headache, 2004, Olesen, 2006).  Out of 
the 12% of the US population that is affected by migraine, 1-2% suffer from chronic 
migraine (Schramm et al., 2013). This means that approximately 5 million people in the 
US alone will suffer from chronic migraine in a given year (Schwedt, 2014). Based on 
data from the American Migraine Prevalence and Prevention Study, the prevalence of 
chronic migraine was highest among females, in mid-life, and in households with the 
lowest annual income (Buse et al., 2012, Buse et al., 2013). Thus, finding new and more 
effective ways to treat this debilitating disorder should be a top priority for the 
pharmaceutical and medical communities.  
  
Chronic Migraine Pathology 
 A pathophysiological feature of migraine is prolonged sensitization, a lowering of 
the activation threshold, of neurons within the central nervous system (CNS) and 
peripheral nervous system that are responsible for transmission of nociceptive (painful) 
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stimuli (Bernstein and Burstein, 2012).  Peripheral sensitization, which is characterized 
by an increase in neuronal excitability and a lowering of the threshold for activation, 
plays an important role in the initiation of a migraine attack.  Based on current models, 
inflammatory mediators are released from trigeminal nerve fibers that provide sensory 
innervation of the meningeal blood vessels that promote neurogenic inflammation in 
response to real or perceived ischemic events within the brain (Noseda and Burstein, 
2013, Burstein et al., 2015).  Neurogenic inflammation is characterized by increased 
blood flow, increased plasma protein extravasation, and recruitment and activation of 
immune cells.  The release of neuropeptides such as calcitonin gene-related peptide 
(CGRP) and other pro-inflammatory molecules including nitric oxide and cytokines are 
responsible for inducing changes in the expression and activity of ion channels and 
receptors on trigeminal neurons that facilitate their sensitization and activation.  With 
respect to episodic migraine, peripheral sensitization, which is characterized by the 
throbbing sensation, promotes development of central sensitization via the release of 
CGRP and other inflammatory mediators within the upper spinal cord.  Central 
sensitization, which is characterized by enhanced excitability of second-order neurons, is 
responsible for the pain associated with a migraine.  More specifically, central 
sensitization is associated with hyperalgesia (an increased pain response) and also 
allodynia (a nocifensive response to non-painful stimuli) (Dodick and Silberstein, 2006, 
Jakubowski et al., 2007).  In episodic migraine attacks, central sensitization typically 
resolves within 4-72 hours if the migraine is not treated with pharmaceuticals.  However, 
in chronic migraine central sensitization can lower the activation threshold of peripheral 
trigeminal neurons, thus promoting peripheral sensitization of trigeminal neurons and a 
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maladaptive filtering of a variety of sensory stimuli including strong odors, foods, 
weather patterns, light, sounds, and even exercise.  Interestingly, these types of stimuli 
are regarded as risk factors or triggers of migraine attacks (Lipton and Bigal, 2005, 
Friedman and De ver Dye, 2009).   
   
Role of the Trigeminal System in Migraine Pathology 
 Both peripheral and central sensitization involve the activation of glial cells that 
are found in close proximity with the cell bodies of primary peripheral and secondary 
central trigeminal neurons (Ren and Dubner, 1999, Davies et al., 2010).  Based on results 
from our studies as well as other studies, increased neuron-glia interactions within the 
trigeminal ganglion and medullary horn of the upper spinal cord are thought to contribute 
to the initiation and maintenance of a sensitized or hyperexcitable state of nociceptive 
neurons (Xie, 2008, Damodaram et al., 2009, Cady et al., 2010, Villa et al., 2010, Cady et 
al., 2011, Cady et al., 2013, Cady et al., 2014).  Sensitization and activation of the 
trigeminal nerve, which results in the release of neuropeptides both in peripheral tissues 
and the CNS that promote inflammatory and nociceptive responses, plays an important 
role in the underlying pathology of migraine. The trigeminal nerve, also known as the 
fifth cranial nerve, is the largest cranial nerve in the human body and is responsible for 
both sensory and motor innervation of the head and face (Shankland, 2000). The 
trigeminal nerve consists of three distinct branches: the ophthalmic branch, the maxillary 
branch, and the mandibular branch (Fig. 1).   While sensitization and activation of the 
ophthalmic branch is strongly implicated in migraine pathology, there is less evidence for 
a direct role of the maxillary and mandibular branches (Bartsch and Goadsby, 2003).   
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 The first division of the trigeminal nerve is the ophthalmic branch (V1). This 
afferent sensory nerve is responsible for relaying information from the scalp, forehead, 
upper eyelid, eyebrow, eye, portions of the nasal cavity, the tentorium cerebelli, posterior 
flax cerebri, and dura mater (Shankland, 2001a).  The dura mater is the protective 
covering of the brain that contains the blood vessels innervated by the V1 branch and 
thought to be activated during a migraine attack (Bolay et al., 2002).  The maxillary 
branch (V2), which is the second sensory division of the trigeminal nerve, innervates the 
lower eyelid, midfacial region, nose, maxillary sinus, mucous membrane of the 
nasopharynx, soft palate, roof of the mouth, maxillary teeth, and palatine tonsil 
(Shankland, 2001b). The third branch of the trigeminal nerve, the maxillary branch (V3), 
consists of both afferent sensory neurons and efferent motor neurons.  The afferent 
sensory neurons carry information from the skin of the lower one-third of the face, the 
ear, lower lip, and temporal region along with the teeth, gingivae of the mandible, and the 
mucus membrane of the anterior two-thirds of the floor of the mouth and tongue. The 
efferent motor neurons innervate the anterior belly of the digastric, mylohyoid, tensor 
tympani, tensory veli palatine, and the muscle of mastication (Shankland, 2001c).  
Although the V2 and V3 branches are not directly implicated in migraine attacks, 
activation of these sensory nerves, which occurs in allergic rhinitis and 
temporomandibular joint disorder, respectively, can promote sensitization of the V1 
branch and thus contribute to migraine pathology. 
 The cell bodies of the pseudounipolar sensory neurons associated with the 
trigeminal nerve are located within the trigeminal ganglion, which lies in a depression of 
the temporal bone, known as Meckle’s cave, in the floor of the middle cranial fossa 
6 
(Shankland, 2000). The sensory trigeminal neurons have peripheral and central processes; 
the peripheral processes extend to the head and face whereas the central processes 
synapse with second order neurons in the spinal trigeminal nucleus (STN) (Fig. 1). These 
nerve fibers can be either Aδ fibers, which are myelinated, or unmyelinated C fibers 
(Lazarov, 2007).  Due to their myelination, Aδ fibers transmit pain and temperature 
signals more quickly than C fibers (Giniatullin et al., 2008).  In addition to the neurons, 
there are two types of glial cells that are found in the trigeminal ganglion: Schwann cells 
and satellite glial cells. Schwann cells are responsible for the myelination of Aδ fibers, 
therefore increasing the speed at which the fibers conduct information, while satellite 
glial cells surround the individual cell bodies and play an important role in the 
modulation of the excitability state of the neuron (Thalakoti et al., 2007, Durham and 
Garrett, 2010).  
 Afferent fibers from the trigeminal ganglion enter the central nervous system at 
the level of the pons, where they synapse with neurons in the trigeminal nuclei 
(Shankland, 2000, 2001c, b, a). The nuclei of the trigeminal nerve extend from the 
cervical spinal cord to the midbrain and consist of three sensory nuclei and one motor 
nucleus. Fibers from the trigeminal ganglion project to two of the sensory nuclei, whereas 
the third sensory nuclei contain fibers that do not pass through the trigeminal ganglion.  
 The mesencephalic nucleus, which is the most superior nucleus, receives 
proprioceptive fibers of mastication and mechanoreceptors from the hard palate and 
temporomandibular joint (Lazarov, 2002). The largest nucleus, which is the principle 
nucleus, receives projections of mostly myelinated fibers from the trigeminal ganglion. 
The most inferior nucleus, which is the STN, receives both lightly myelinated and 
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unmyelinated fibers from V1, V2, and V3 of the trigeminal nerve. Within the STN, there 
are three subnuclei: the subnucleus oralis, the subnucleus interpolaris, and the subnucleus 
caudalis, the site implicated in migraine pathology (Noseda and Burstein, 2013). This 
region of the medullary horn receives input from the trigeminal nerves that provide 
sensory innervation of the cerebral and meningeal blood vessels, and thus is a common 
pathway for migraine pain signaling.  Based on work by Burstein and colleagues, V1 
primary nociceptive neurons terminate primarily in outer laminas I and II of the 
medullary horn where they synapse with second order neurons that send projections to 
the thalamus (Fig. 1).  Fiber projections from the thalamus to the cortex complete the 
ascending pain pathway referred to as the spinothalamic tract that is responsible for the 
perception of nociceptive stimuli as painful (Burstein et al., 2015).    
 
Proteins Implicated in the Development of Peripheral and Central Sensitization  
 Changes in the expression and activity level of ion channels and receptors that 
function to control the level of neuronal excitability is mediated by a number of signaling 
proteins expressed in neurons and associated glial cells (Sun et al., 2004, Cheng and Ji, 
2008, Ji et al., 2009, Cady et al., 2011).  Sustained upregulation of key signaling proteins 
is implicated in the development of a primed state of the nociceptive neurons, which is a 
pathophysiological state characteristic of chronic pain (Hucho and Levine, 2007).  The 
following proteins are associated with a hyperexcitable state of nociceptive neurons:  
protein kinase A (PKA), glial fibrillary associated protein (GFAP), and ionized calcium-
binding adapter molecule Iba1 (Ji et al., 2013).  Increased expression of PKA has been 
reported in trigeminal ganglia and spinal cord in response to peripheral inflammation of 
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tissues of the head and face (Levy and Strassman, 2002, Cady et al., 2011).  PKA is 
activated by a number of inflammatory agents that mediate increased intracellular levels 
of the secondary messenger cAMP (Aley and Levine, 1999, Kim et al., 2006).  Following 
binding of cAMP to PKA, the enzyme can phosphorylate proteins involved in 
intracellular signaling pathways, including receptors, ion channels, and transcription 
factors to modulate their activity within the cell.  Typically in neurons and glial cells, 
elevated levels of PKA result in an increase in the synthesis and release of pro-
inflammatory molecules such as cytokines and nitric oxide as well as changes in ion 
channels and receptors to promote a more hyperexcitable state of trigeminal neurons 
(Hanada and Yoshimura, 2002, Gosselin et al., 2010).   
 In response to trigeminal activation by thermal, mechanical, or chemical stimuli, 
trigeminal neurons release inflammatory molecules that can then cause activation of the 
associated glial cells both in the ganglion and STN (Ren and Dubner, 2008, Ren, 2009, 
Durham and Garrett, 2010).  Furthermore, increased neuron-glia communication via gap 
junctions and paracrine signaling is thought to play an important role in the initiation and 
maintenance of peripheral and central sensitization.  Within the CNS, activation of 
astrocytes and microglia is a well-documented cellular phenomenon that directly 
correlates with the level of neuronal excitability and pain.  The intermediate filament 
protein GFAP is often used as a marker of activated astrocytes while the calcium binding 
adapter protein Iba1 is utilized as a marker of activated microglia.  Changes in GFAP 
expression coincide with structural changes in astrocytes associated with migration and 
synthesis and release of cytokines and chemokines (Guo et al., 2007).  Elevated levels of 
Iba1 in microglia are associated with increased proliferation, migration, and an increase 
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in the production and secretion of pro-inflammatory cytokines and chemokines (Ohsawa 
et al., 2004, Villa et al., 2010).  Thus similar to astrocytes, microglial activation serves a 
protective role within the CNS to facilitate cellular events to repair damaged tissues and 
restore tissue homeostasis (Ikeda et al., 2012).   
 
Treatment of Migraine 
 The treatment of migraine is generally divided into acute and preventative 
(Silberstein, 2006, Cady et al., 2012a).  While acute treatments are used intermittently to 
reverse a migraine attack that has already begun, preventative therapeutics are typically 
taken on a daily basis to quiet the nervous system so as to minimize or block the 
development of future migraines.  Despite a wide array of treatments being available, 
migraine continues to be a leading cause of disability because of being misdiagnosed, 
underdiagnosed, and inadequately treated (Lipton et al., 2011).  The primary goals of 
migraine pharmacology are to reduce the frequency and severity of attacks and thus 
significantly decrease the amount of physical, social, and psychological disability.  Many 
of the drugs currently used to treat episodic or chronic migraine were originally 
developed to reduce the frequency, duration, and severity of seizures associated with 
epilepsy  (Mathew, 2001).  One such drug is Topiramate, which was initially investigated 
for its ability to block epileptic seizures and only later was approved as a prophylactic 
treatment of frequent migraine.  Results from open-label and small controlled studies 
provided evidence that Topiramate, a structurally distinct antiepileptic drug, could be 
efficacious in migraine prevention (Diener et al., 2004, Diener et al., 2007).  More 
recently, data from 2 multicenter, randomized, double-blind, placebo-controlled trials 
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established the efficacy of Topiramate to significantly reduce the frequency and severity 
of migraine attacks (Silberstein, 2005).  In addition, Topiramate exhibited high responder 
rates, good tolerability, and a lack of major contraindications.  Topiramate is arguably the 
best studied and most efficacious migraine preventive for patients with frequent episodic 
migraine.  Although the exact cellular mechanisms of action are not known, Topiramate 
is thought to function by reducing neuronal hyperexcitability and release of inflammatory 
molecules through several possible mechanisms: a state-dependent blocking of sodium 
channels, augmentation of GABA activity, antagonism of AMPA/kainate glutamate 
receptors, or inhibition of carbonic anhydrase.  However, even though Topiramate is 
generally well-tolerated in most patients, there have been reports of severe adverse events 
and relatively high drop-out rates in both clinical trials and clinical practice.   
 Another class of drugs that are used in the treatment of migraine is the opiates 
even though they are not recommended as first-line therapy because of the high risk of 
developing medication overuse headache (Saper and Da Silva, 2013).  Their use is 
appropriate in patients that cannot tolerate, do not respond to, or have contraindications to 
standard migraine abortive drugs since they exert a strong analgesic response (Loder et 
al., 2013).  Opioids are most commonly utilized in patients that are seen in the emergency 
department of hospitals since often headache specialists will not be on staff.   In general, 
guidelines from the American Academy of Neurology and American Headache Society 
advocate for the limited use of opioids by clinicians in the treatment of migraine because 
they are not as effective as other migraine approved drugs and treat the symptoms rather 
than the migraine process.  For example, results from a large double-blind placebo-
controlled study compared sumatriptan/naproxen, butalbital/ acetaminophen/ caffeine/ 
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codeine, and placebo in a population of severely impacted migraine subjects who in the 
past had used a butalbital-containing product (opioid) (Derosier et al., 2012).  Compared 
to the butalbital combination and placebo groups, the subjects who took sumatriptan/ 
naproxen reported a greater incidence of being pain- free or achieving pain relief.  
Despite our advances in the treatment of migraine, there still remains a clear need for 
safer and more effective drugs for managing acute and chronic migraine. 
 
Goals of My Study 
 The primary goal of my study was to determine the effect of two novel anti-
migraine drugs, designated as Drug A and Drug B, and compare their mechanism of 
action to Topiramate and the opioid Buprenorphine in an animal model that mimics 
trigeminal system pathology associated with frequent and chronic migraine.  I wanted to 
test the hypothesis that these novel drugs would be able to inhibit ongoing peripheral and 
central sensitization of trigeminal nociceptors, and hence pain transmission.  To 
accomplish my goal, I utilized behavioral and cellular techniques to investigate the 
effects of each of these drugs in a well-established model of chronic trigeminal nerve 
activation.  Briefly, the pro-inflammatory agent, complete Freund’s adjuvant (CFA), was 
injected in the TMJ capsule to cause sustained sensitization of trigeminal neurons and the 
ability of each drug to inhibit ongoing sensitization investigated.   
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Figure 1. Schematic representation of trigeminal nociceptive pathway from peripheral 
tissue through the ganglion and then to the second order neurons and finally the 
thalamus.  See text for details. 
TG Thalamus 
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METHODS 
 
Animals and Drugs 
All of the animal procedures in this study were reviewed and approved by the 
Institutional Animal Care and Use Committee of Missouri State University (Protocol 
number14-021.0-A approved on 03/13/2014). Every effort was made to minimize animal 
suffering and to use the minimum number of animals required for this study. Adult male 
Sprague-Dawley rats (350-500 g; Charles River Laboratories Inc., Wilmington, MA) 
were individually housed in clean plastic cages on a 12-hour light/dark cycle with 
unrestricted access to food and water.  Upon arrival in our facility, all animals were 
housed for up to 7 days before being released for my studies. 
The novel drugs, designated simply as Drug A and Drug B, used in my study 
were kindly provided by the pharmaceutical company Upsher-Smith Laboratories (Maple 
Grove, MN).  Drug A was diluted to a concentration of 10 mg/mL in dimethyl sulfoxide 
(DMSO) while Drug B was diluted to a concentration of 30 mg/mL in 20% TPGS 
(vitamin E). Topiramate, which was purchased by Upsher-Smith and provided to our 
laboratory, was prepared at a 50 mg/mL concentration in DMSO.   Buprenorphine 
hydrochloride (0.3 mg/ml) was obtained from Patterson Veterinary (Devens, MA).  All 
drugs were made up as stock solutions in appropriate vehicle solvent and stored at -20 °C 
for future use.  Complete Freund’s adjuvant (CFA; Sigma-Aldrich, St. Louis, MO, USA) 
was prepared just prior to administration as a 1:1 CFA/0.9% sodium chloride (saline) 
emulsion.  
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Behavioral Testing in Response to Prolonged Trigeminal Activation 
 The measurement of changes in nocifensive response to mechanical stimulation in 
the orofacial region of the rat was performed as described in recent publications from the 
Durham Lab (Garrett et al., 2012, Cady et al., 2014, Hawkins et al., 2015). For three 
consecutive days prior to testing, the rats were acclimated to the Durham Holder (Ugo 
Basile, Milan, Italy) (Fig. 2).   Each rat was guided into the Durham Holder and kept 
there for 5 minutes to familiarize the rat with the device. While in the device, a pipette tip 
was used to stimulate the area over each TMJ region (30 sec on each side for the duration 
of the 5 min) to acclimate the rat to having the TMJ region touched with a filament. If a 
rat was consistently uncooperative during this acclimation period, the animal was 
removed from the study.  
 Prior to injection, basal mechanical withdrawal responses were measured in the 
Durham Holder using different force von Frey filaments (60, 100, 180 grams). The 
filaments were applied five times on the left and right side of the animal to stimulate the 
trigeminal neurons that innervate the TMJ region.  Both the researcher who recorded the 
response and the researcher who physically stimulated the animal were blinded to the 
experimental conditions being tested. A positive response was indicated by head 
withdrawal prior to the bending of the filament.  If the animal had less than three 
withdrawal responses to the 60 g filament, the 100 g and then 180 g filaments were used 
until the animal had three or more withdrawal responses to a given filament (Fig. 3).  
 After baseline threshold nocifensive responses were obtained, the animals were 
anesthetized by inhalation of 5% isoflurane.  As shown by previous studies in our 
laboratory, bilateral injection of CFA promotes a sustained (chronic) activation of the 
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trigeminal system (Garrett and Durham, 2009, Cady and Durham, 2010, Cady et al., 
2014).  Based on prior results using this model, anaesthetized animals were given 
bilateral injections of either 50 µL CFA (1:1 CFA/saline) or saline as a vehicle control in 
the TMJ capsule.  Animals received Drug A (10 mg/kg; intraperitoneal or IP) or Drug B 
(30 mg/kg; per os or PO gavage) on days 3 and 4 post CFA injection, or Topiramate (50 
mg/kg, IP) daily up through day 4 post CFA injection, or equivalent volume of vehicle 
(Fig. 4).  DMSO was used as the vehicle since it was used as the drug solvent.  Dosage 
and mode of administration for Topiramate was based on a previously published study 
(Wieczorkiewicz-Plaza et al., 2004) on the effect of Topiramate on mechanical allodynia 
in rats. Other male Sprague-Dawley rats were left untreated to serve as naïve controls.  
The rationale for administration of Drug A and Drug B on days 3 and 4 post CFA 
injection is based on the knowledge that nocifensive behaviors peak around day 5      
post-injection. Topiramate was administered daily since it is approved as a prophylactic 
drug for frequent migraine. The opioid drug, Buprenorphine hydrochloride (0.05 mg/kg), 
was injected subcutaneously in the hindquarter two hours prior to mechanical testing.  In 
a previous study, our laboratory used Buprenorphine as a control drug since it is known 
to block peripheral pain transmission (Garrett et al., 2012).   Using the same method that 
was used for the baseline responses, the number of nocifensive responses were recorded 2 
hours and 3, 5, 10, and 14 days post CFA injection for each experimental condition. The 
data were reported as the average number of responses obtained from a total of 10 
applications of each specific calibrated filament (5 applications on each side of the face).    
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Cellular Evaluation 
 Using the same injection method as stated earlier, 50 µL of CFA or saline alone 
(control) was injected into both TMJ capsules to cause prolonged activation of trigeminal 
sensory neurons. Some animals received Drug A (10 mg/kg, IP) or Drug B (30 mg/kg, 
PO) on days 3 and 4 post CFA injection, or Topiramate (50 mg/kg, IP) daily up through 
day 4 post CFA injection, or equivalent volume of vehicle to determine if the drugs are 
capable of blocking the sustained stimulatory effect of CFA on trigeminal neurons that 
promote prolonged peripheral and central sensitization (Fig. 5).  
 Five days post CFA injection, animals were sacrificed by CO2 asphyxiation and 
decapitation. Both trigeminal ganglion as well as the upper spinal cord tissue (4-5 mm 
posterior to the obex) containing the STN were removed and immediately placed in 4% 
paraformaldehyde at 4°C overnight. Following paraformaldehyde fixation, tissues were 
sucrose fixed in 12.5% sucrose at 4°C for one hour, then placed in a 25% sucrose 
solution at 4°C overnight. Tissues were removed from the sucrose solution the following 
day and stored at -20°C for further immunohistochemical analysis.  
 Prior to cryosectioning, the ganglia were mounted in Optimal Cutting 
Temperature (OCT) compound (Sakura Finetek, Torranc, CA) such that the ventral 
surface was in contact with the upper surface of a Superfrost Plus slide (Fisher Scientific, 
Pittsburgh, PA), quickly frozen, and stored at -20°C. Fourteen micron longitudinal 
sections of the entire trigeminal ganglion tissue were serially prepared using a cryostat 
(Microm HM 525, Thermo Scientific, Waltham, MA) set at -24°C. A total of 20 slides 
were prepared to ensure that sections from the middle of the ganglion, which contain cell 
bodies from all three branches (V1-V3), were obtained. The slides that contained sections 
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from the middle of the ganglion were chosen for immunohistochemistry. For the spinal 
cord samples, tissues were positioned with the caudal side in contact with the slide, 
covered with OCT, quickly frozen, and stored at -20°C. Spinal cord sections (14 µm) 
containing the STN were sectioned transversely at a distance of 4-5 mm posterior to the 
obex using a cryostat set at -24°C. As with the trigeminal ganglion, multiple slides were 
prepared to ensure that the sections used for immunohistochemistry were from the correct 
area of the tissue (STN; 71 sections ≈ 1 mm).  In addition, each slide contained at least 
one section for each experimental condition: naïve, vehicle, CFA, and CFA + Drug A, 
CFA + Drug B, or CFA + Topiramate.  
 Slides containing sections of ganglia or spinal cord, which had been stored at -
20°C, were hydrated with 1x Phosphate Buffered Saline Solution (PBS; Sigma-Aldrich) 
for 5 minutes and then incubated in a solution of 0.1% Triton X-100 and 5% donkey 
serum (Jackson Immuno Research Laboratories, West Grove, PA) for 20 minutes. Next, 
slides were rinsed 5 times with PBS and then incubated with primary antibodies diluted 
in 5% donkey serum for 3 h at room temperature and then with secondary antibodies 
diluted in PBS for 1 h at room temperature.  A complete list of the antibodies used in my 
study is shown in Table 1.  As a control, some slides were incubated with only secondary 
antibodies. None of the secondary antibodies used in my study exhibited staining levels 
above those observed when primary antibodies were omitted.  Sections were mounted 
using Vectashield medium (H-1200) containing 4’, 6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories, Burlingame, CA) to co-stain cell nuclei. Images (20x) were 
collected using a Zeiss Axiocam mRm camera mounted on a Zeiss Imager Z2 fluorescent 
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microscope equipped with an ApoTome. Image acquisition was performed using Zeiss 
Zen Blue 2011 (Thornwood, NY).  
 
Statistical Analysis 
 For the behavioral studies, the data are reported as the average number of 
withdrawal responses ± SEM to the von Frey filament force at each time point.   The 
number of animals used for each experimental condition are provided in Tables 2 and 3.  
Statistical analysis was performed using a Factorial with Independent t-test with 
Bonferroni correction between groups in SPSS 20 software.  Differences are considered 
to be significant at p < 0.05.  
 The relative staining intensity measurements in trigeminal ganglia and spinal cord 
tissues were based on previously published protocols from the Durham Lab (Cady et al., 
2010, Cady et al., 2011, Cady et al., 2014, Hawkins et al., 2015). Zen software (Carl 
Ziess) was utilized to evenly balance the background of each image prior to analysis. For 
trigeminal ganglia, four randomly chosen 20x images containing a similar number of 
neuronal and glial cells in the V1/V2 region, as identified by the nuclear dye DAPI, were 
opened in ImageJ software (NIH) and analyzed for each experimental condition that were 
repeated in at least four independent experiments.  This resulted in a minimum of 16 
fluorescent images being analyzed for the intensity measurements. The fluorescent 
staining intensity in spinal cord tissue was determined by measuring the mean gray 
intensity from ten regions, in laminas I-III, of staining in the medullary horn and 
subtracting the background intensity from acellular regions of the medullary horn in a 
minimum of four independent experiments. This resulted in a minimum of 40 fluorescent 
19 
images being analyzed for the intensity measurements in the spinal cord tissues for each 
experimental condition. As with the trigeminal ganglia, ImageJ software (NIH) was used 
for this analysis. 
 The fold-change in staining intensity is defined as the mean change in relative 
intensity in the experimental condition when compared to the mean of the unstimulated 
control (naïve) tissue whose average value was made equal to one.  Changes in 
immunostaining intensity were evaluated using a One-Way ANOVA with Tukey post-
hoc tests between groups.  Results were reported as mean ± SEM and were considered 
significant when p < 0.05.  All statistical tests were performed using SPSS (Version 20, 
IBM, Chicago, IL).      
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Table 1. Summary of Antibodies Used for Immunohistochemistry. 
 
Antibody Host Supplier Dilution Incubation 
PKA Rabbit Abcam 1:500 3 h 
Iba-1 Goat Abcam 1:400 3 h 
GFAP Goat Abcam 1:5000 3 h 
NeuN Mouse Millipore 1:10,000 3 h 
Alexa 488 Rabbit Invitrogen 1:200 1 h 
Alexa 568 Goat Invitrogen 1:200 1 h 
Alexa 647 Mouse Invitrogen 1:200 1 h 
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Table 2.  Summary of Treatments and Number of Animals Used for Behavioral Studies.  
 
 
 
Group Number Treatment Number Used 
1 Naïve Control 10 
2 CFA TMJ + Saline IP 10 
3 CFA TMJ + Saline PO 10 
4 CFA TMJ + Saline SC 10 
5 CFA TMJ+ Drug A IP 10 
6 CFA TMJ + Drug B PO 10 
7 CFA TMJ + Topiramate IP 10 
8 CFA TMJ + Buprenorphine SC 10 
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Table 3. Summary of Treatments and Animals Used for Immunohistological Studies.  
 
Group Number Treatment Number Used 
1 Naïve Control 4  
2 Saline TMJ+ Saline IP 4 
3 Saline TMJ+ Saline PO 4 
4 Saline TMJ+ PRX201145 IP 4 
5 Saline TMJ+ PRX201260 PO 4 
6 Saline TMJ + Topiramate IP 4 
7 CFA TMJ + Saline IP 4 
8 CFA TMJ + Saline PO 4 
9 CFA TMJ+ PRX201145 IP 4 
10 CFA TMJ + PRX201260 PO 4 
11 CFA TMJ + Topiramate IP 4 
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Figure 2. A rat being acclimated to the Durham Holder prior to testing nocifensive 
response to mechanical stimulation of the cutaneous region near the TMJ.  Slits were 
cut into the commercially available device to allow for mechanical stimulation of 
orofacial region. 
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Figure 3. Picture of two von Frey filaments used in my study. The 60 g von Frey 
filament is shown on the left while a 100 g von Frey filament is shown on the 
right.   Notice that the filament on the right is thicker than the one on the left, so 
it produces a greater force when applied to the animal. 
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A. 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Relative behavioral timelines in days for treatment with Drug A and Drug B 
(A), Topiramate (B), and Buprenorphine (C) are shown.  The CFA pain response curve is 
shown above the timeline. 
 
  
C.  
* = CFA or Saline Injection 
# = Vehicle, Drug A, or Drug B Treatment 
RED = von Frey Testing 
* = CFA or Saline Injection 
# = Vehicle or Topiramate Treatment 
RED = von Frey Testing 
* = CFA or Saline Injection 
# = Vehicle or Buprenorphine Treatment 
RED = von Frey Testing 
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* = CFA 
# = Saline, Drug A, or Drug B treatment  
(Topiramate administered daily through day 4) 
RED = Tissue Collection 
Figure 5. A relative timeline in days for CFA injection, treatments, and 
tissue collection. The CFA pain response curve is shown above the 
timeline. 
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RESULTS 
 
Behavioral Testing in Response to Prolonged Trigeminal Activation 
Behavioral testing was performed to determine whether the administration of 
Drug A, Drug B, or Topiramate could reduce the number of nocifensive withdrawal 
responses to mechanical stimulation of trigeminal sensory neurons in a chronic 
inflammatory model.  Each von Frey filament (60, 100, 180 g) was applied 5 times to the 
cutaneous area in the TMJ region on the left and right side of each animal and the number 
of withdrawals was recorded.  A positive, nocifensive response was defined as occurring 
if the animal withdrew from a given filament 3 or more times out of 5 tests.  As seen in 
Figure 6, no difference was observed in the baseline values for any of the experimental 
conditions with all being below 1.0 on average.  Since rats injected with CFA exhibited a 
large and consistent increase in the number of nocifensive responses to the 100 g filament 
at the 2 hour time point while the saline and vehicle control did not, the 100 g filament 
was used for testing at all other later time points.     
Animals injected with 50 µL of saline followed by treatment with the vehicle 
withdrew from the 100 g filament an average of 0.4 times at baseline, 0.8 times 2 hours 
post saline injection, 0.5 times on day 3, 0.8 times on day 5 following injection of 
vehicle, 0.3 times on day 7, 0.6 times on day 10, and 0.8 times on day 14. In comparison, 
animals injected with 50 µL saline followed by Drug A (10 mg/kg) on days 3 and 4 
withdrew from the 100 g filament an average of 0.4 times at baseline, 0.3 times 2 hours 
after saline injection, 0.4 times on day 3, 1.1 times on day 5 following injection of Drug 
A, 0.8 times on day 7, 0.8 times on day 10, and 0.9 times on day 14. However, animals 
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injected with 50 µL of CFA withdrew from the 100 g filament an average of 0.5 times at 
baseline, 4.3 times 2 hours after CFA injection, 4.3 times on day 3, 4.5 times on day 5 
following injection of vehicle, 4.9 times on day 7, 4.8 times on day 10, and 3.9 times on 
day 14. Finally, animals injected with 50 µL CFA followed by Drug A (10 mg/kg) 
withdrew from the 100 g filament an average of 0.8 times at baseline, 4.1 times 2 hours 
after CFA injection, 4.9 times on day 3, 1.8 times on day 5 following injection of drug A, 
3.3 times on day 7, 3.2 times on day 10, and 3.8 times on day 14.  On day 5, Drug A 
administration caused a significant decrease in the number of nocifensive withdrawals 
when compared to CFA values.  However, I observed no difference between CFA alone 
and CFA followed by treatment with Drug A on subsequent days.   
The average number of withdrawal responses for both the left and right side to the 
100 g filament for administration of Drug B on days 3 and 4 post CFA injection can be 
seen in Figure 7. Animals injected with 50 µL of saline and vehicle withdrew from the 
100 g filament an average of 0.1 times at baseline, 0.5 times 2 hours after saline injection, 
0.4 times on day 3, 0.4 times on day 5 following gavage of vehicle (vitamin E), 0.7 times 
on day 7, 0.4 times on day 10, and 0.4 times on day 14. Animals injected with 50 µL 
saline followed by Drug B (30 mg/kg) withdrew from the 100 g filament an average of 
0.6 times at baseline, 0.9 times 2 hours after saline injection, 0.6 times on day 3, 0.9 times 
on day 5 following gavage of Drug B, 1.0 times on day 7, 0.7 times on day 10, and 1.1 
times on day 14. Animals injected with 50 µL of CFA withdrew from the 100 g filament 
an average of 0.5 times at baseline, 4.5 times 2 hours after CFA injection, 4.6 times on 
day 3, 4.5 times on day 5 following gavage of vehicle (vitamin E), 4.1 times on day 7, 4.3 
times on day 10, and 4.1 times on day 14. Finally, animals injected with 50 µL of CFA 
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followed by Drug B (30 mg/kg) withdrew from the 100 g filament an average of 0.5 
times at baseline, 4.4 times 2 hours after CFA injection, 4.5 times on day 3, 1.3 times on 
day 5 following gavage of drug B, 1.6 times on day 7, 2.4 times on day 10, 3.7 times on 
day 14.  On days 5, 7, and 10, Drug B administration caused a significant decrease in the 
number of nocifensive withdrawals when compared to CFA values.  However, no 
difference between CFA and Drug B was observed on day 14.   
The average number of withdrawal responses for both the left and right side to the 
100 g filament following daily administration of Topiramate can be seen in Figure 8. 
Animals injected with 50 µL of saline and vehicle withdrew from the 100 g filament an 
average of 0.4 times at baseline, 0.8 times 2 hours after saline injection, 0.5 times on day 
3, 0.8 times on day 5 following injection of vehicle, 0.3 times on day 7, 0.6 times on day 
10, and 0.8 times on day 14. Animals injected with 50 µL saline followed by Topiramate 
(50 mg/kg) withdrew from the 100 g filament an average of 1.3 times at baseline, 0.7 
times 2 hours after saline injection, 0.8 times on day 3, 1.2 times on day 7 following 
injection of Topiramate, 1.9 times on day 10, and 1.4 times on day 14. Animals injected 
with 50 µL CFA withdrew from the 100 g filament an average of 0.5 times at baseline, 
4.3 times 2 hours after CFA injection, 4.3 times on day 3, 4.5 times on day 5 following 
injection of vehicle, 4.9 times on day 7, 4.8 times on day 10, and 3.9 times on day 14. 
Finally, animals injected with 50 µL CFA followed by Topiramate (50 mg/kg) withdrew 
from the 100 g filament an average of 0.5 times at baseline, 4.6 times 2 hours after CFA 
injection, 4.8 times on day 3, 4.5 times on day 5 following Topiramate injection, 4.7 
times on day 7, 4.9 times on day 10, and 4.7 times on day 14.   In contrast to Drug A and 
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Drug B results, Topiramate did not inhibit CFA mediated nocifensive responses on any of 
the days post administration.   
To test the effect of an opioid in my model, I measured the average number of 
withdrawal responses for both the left and right side to the 100 g filament following 
administration of Buprenorphine on days 3 and 4.  As seen in Figure 9, animals injected 
with 50 µL of saline withdrew from the 100 g filament an average of 0.4 times at 
baseline, 0.8 times 2 hours after saline injection, 0.5 times on day 3, 0.5 times on day 4, 
0.8 times on day 5, 0.3 times on day 7, 0.6 times on day 10, and 0.8 times on day 14. 
Animals injected with 50 µL of CFA withdrew from the 100 g filament an average of 0.5 
times at baseline, 4.3 times 2 hours after CFA injection, 4.3 times on day 3, 4.3 times on 
day 4, 4.5 times on day 5, 4.9 times on day 7, 4.8 times on day 10, and 3.9 times on day 
14. Animals injected with 50 µL of CFA followed by Buprenorphine (0.05 mg/kg) 
withdrew from the 100 g filament an average of 0.5 times at baseline, 5.0 times 2 hours 
after CFA injection, 0.0 times on day 3 and day 4 (Buprenorphine was administered 30 
minutes prior to testing), 5.0 times on day 5, 3.5 times on day 7, 3.8 times on day 10, and 
4.0 times on day 14.  On days 3 and 4, which correspond to the delivery of 
Buprenorphine, there was a significant decrease in the number of nocifensive 
withdrawals when compared to CFA values on those days.  However, Buprenorphine 
caused only a transient inhibition since no difference was observed between CFA and 
drug treatment on days 5, 7, 10, or 14.   
 
Effect of Drugs on PKA Levels in the Trigeminal Ganglia 
Trigeminal nerves were dissected, fixed, and stained for changes in PKA levels in 
the V1/V2 region of the trigeminal ganglion using immunohistochemistry. In naïve 
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animals, PKA immunostaining was detected at low levels in neurons in the trigeminal 
ganglion.  Additionally, animals that received saline injections followed by injection of 
either DMSO or Drug A exhibited low levels of PKA as well (Fig. 10). However, in 
animals that received CFA injections followed by injection of DMSO, significantly 
elevated levels of PKA  (2.46 ± 0.22, p < 0.01) were detected in the trigeminal ganglion 
compared to levels in naive rats (1.00 ± 0.08).  In animals that received CFA injections 
followed by treatment with Drug A, PKA was detected at decreased levels (1.21 ± 0.19, p 
< 0.01) in the trigeminal ganglion compared to levels in animals that had received CFA + 
DMSO injections (2.46 ± 0.22).  
 Animals that received saline injections followed by gavages of Vitamin E or Drug 
B exhibited low levels of PKA in the V1/V2 region of the trigeminal ganglion (Fig. 11).  
Conversely, the animals injected with CFA followed by a Vitamin E gavage exhibited 
high levels of PKA expression (2.38 ± 0.17, p < 0.01) in neurons when compared to 
animals that received the saline + Vitamin E treatment (1.00 ± 0.14). Animals that were 
treated with Drug B following CFA injections had greatly decreased levels of PKA  
(1.10 ± 0.12, p < 0.01) in the trigeminal ganglion compared to levels in animals that had 
received CFA + Vitamin E treatment (2.38 ± 0.17, p < 0.01).  
 For this condition, the naïve animals exhibited low levels of PKA in the V1/V2 
region of the trigeminal ganglion. In addition, PKA immunostaining was detected at low 
levels in neurons and satellite glia cells in the trigeminal ganglion of animals that 
received saline injections followed by either DMSO or Topiramate injections (Fig. 12). 
Animals injected with CFA followed by a DMSO injection exhibited high levels of PKA 
expression (2.88 ± 0.33, p < 0.01) when compared to naïve animals  
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(1.10 ± 0.10).  Interestingly, the animals that were injected with CFA then treated with 
Topiramate expressed higher levels of PKA (2.74 ± 0.24, p < 0.01) in the trigeminal 
ganglion.   
 
Effect of Drugs on PKA Levels in the Spinal Trigeminal Nucleus 
 The upper spinal cord tissue containing the STN was dissected out and changes in 
PKA levels were determined using immunohistochemistry. In animals injected with 
saline followed by DMSO or Drug A injections, low levels of PKA were detected in the 
spinal trigeminal nucleus (Fig. 13). In contrast, the level of PKA staining was 
significantly higher in animals injected with CFA followed by DMSO (1.96 ± 0.09, p < 
0.01) compared to levels in animals that had received saline + DMSO injections (1.00 ± 
0.07). Animals that received CFA injections followed by treatment with Drug A had 
lower levels of PKA expression (1.33 ± 0.11, p < 0.01) in the STN compared levels in 
animals that had received CFA + DMSO injections (1.96 ± 0.09, p < 0.01).  
 Animals that received saline injections followed by gavages of Vitamin E or Drug 
B exhibited low levels of PKA in the spinal trigeminal nucleus (Fig. 14). Expression of 
PKA was significantly increased (2.31 ± 0.26, p < 0.01) in the STN of animals that 
received CFA injections followed by Vitamin E gavage when compared to PKA levels in 
animals that received the saline + Vitamin E treatment (1.00 ± 0.10). Animals that were 
treated with Drug B following CFA injections had greatly decreased levels of PKA (1.16 
± 0.11, p < 0.01) in the outer laminas of the STN compared to levels in animals that had 
received CFA + Vitamin E treatment (2.31 ± 0.26).  
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 The naïve animals exhibited low levels of PKA in the STN. Similarly, PKA 
immunostaining was detected at low levels in the outer laminas of animals that received 
saline injections followed by either DMSO or Topiramate injections (Fig. 15). Animals 
injected with CFA followed by a DMSO injection exhibited significantly higher levels of 
PKA expression (1.79 ± 0.13, p < 0.01) when compared to naïve animals (1.00 ± 0.07). 
Interestingly, the animals that were injected with CFA then treated with Topiramate still 
had higher levels of PKA expression (1.84 ± 0.14, p < 0.01) in the STN.   
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Figure 6.  Drug A transiently inhibits nocifensive response to mechanical stimulation of 
the trigeminal nerve. The cut-off for a positive nocifensive response was set at 3 
withdrawals from 5 applications.  Values are reported as the average number of 
withdrawal responses to mechanical stimulation (out of 5 applications to each side; 100 g 
von Frey filament).  * = p < 0.01 when compared to CFA value. 
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Figure 7.  Drug B mediated sustained inhibition of CFA-mediated nocifensive response 
to mechanical stimulation of the trigeminal nerve.   Red line at 3.0 responses was set as 
the cut-off for a positive nocifensive response.  Values are reported as the average 
number of withdrawal responses to mechanical stimulation (out of 5 applications to each 
side; 100 g von Frey filament).  * = p < 0.01 when compared to CFA value. 
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Topiramate administered 
on Days 1, 2, 3, and 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Topiramate does not inhibit nocifensive response to mechanical stimulation of 
the trigeminal nerve. Red line at 3.0 responses was set as the cut-off for a positive 
nocifensive response. Values are reported as the average number of withdrawal responses 
to mechanical stimulation (out of 5 applications to each side; 100 g von Frey filament). 
  
Saline + Vehicle CFA + Vehicle CFA + Topiramate Saline + Topiramate 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
Baseline 2 Hour Day 3 Day 5 Day 7 Day 10 Day 14 
Saline or CFA 
Injection 
Nocifensive Response 
(Average Number of Withdrawals) 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Buprenorphine treatment completely inhibits CFA-mediated nocifensive 
response to mechanical stimulation of the trigeminal nerve.  Red line at 3.0 responses was 
set as the cut-off for a positive nocifensive response.  Values are reported as the average 
number of withdrawal responses to mechanical stimulation (out of 5 applications to each 
side; 100 g von Frey filament).  
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Figure 10.  Drug A inhibits CFA-mediated stimulation of PKA expression in trigeminal 
ganglion neurons.  Drug A was administered on day 3 and 4 post CFA injection and 
trigeminal ganglia removed on day 5 for immunohistochemistry.  A representative image 
is shown for each experimental condition. 
Condition Relative Intensity of PKA Staining (Mean +/- SEM) 
Naïve 1.00 ± 0.08 
Saline + DMSO 1.09 ± 0.13 
Saline + Drug A 1.13 ± 0.11 
CFA + DMSO 2.46 ± 0.22 * 
CFA + Drug A 1.21 ± 0.19 # 
  
 * = p < 0.01 when compared to Naïve 
 # = p < 0.01 when compared to CFA 
Naive 
Saline + DMSO Saline + Drug A 
CFA + DMSO CFA + Drug A 
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Figure 11.  Drug B inhibits CFA-mediated stimulation of PKA expression in trigeminal 
neurons.  Drug B was administered on day 3 and 4 post CFA injection and trigeminal 
ganglia removed on day 5 for immunohistochemistry.  A representative image is shown 
for each experimental condition. 
 
 
 
Condition Relative Intensity of PKA Staining (Mean +/- SEM) 
Saline + Vitamin E 1.00 ± 0.14 
Saline + Drug B 0.98 ± 0.09 
CFA + Vitamin E 2.38 ± 0.17 * 
CFA + Drug B 1.10 ± 0.12 # 
  
 * = p < 0.01 when compared to Saline + Vitamin E 
 # = p < 0.01 when compared to CFA + Vitamin E 
Saline + Vitamin E Saline + Drug B 
CFA + Vitamin E CFA + Drug B 
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Figure 12.  Topiramate does not inhibit CFA-mediated stimulation of PKA expression in 
trigeminal neurons.  Topiramate was administered on day 3 and 4 post CFA injection and 
trigeminal ganglia removed on day 5 for immunohistochemistry.  A representative image 
is shown for each experimental condition. 
Condition Relative Intensity of PKA Staining (Mean +/- SEM) 
Naïve 1.10 ± 0.10 
Saline + DMSO 1.16 ± 0.11 
Saline + Topiramate 1.18 ± 0.13 
CFA + DMSO 2.88 ± 0.33 * 
CFA + Topiramate 2.74 ± 0.24 
  
 * = p < 0.01 when compared to Naïve 
Naive 
Saline + DMSO Saline + Topiramate 
CFA + DMSO CFA + Topiramate 
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Condition Relative Intensity of PKA Staining (Mean +/- SEM) 
Saline + DMSO 1.00 ± 0.07 
Saline + Tonabersat 1.11 ± 0.15 
CFA + DMSO 1.96 ± 0.09 * 
CFA + Drug A 1.33 ± 0.11 # 
  
 * = p < 0.01 when compared to Saline + DMSO 
 # = p < 0.01 when compared to CFA 
 
 
Figure 13.  Drug A inhibits CFA-mediated stimulation of PKA expression in spinal 
trigeminal nucleus.  Drug A was administered on day 3 and 4 post CFA injection and 
upper spinal cord tissue containing the spinal trigeminal nucleus removed on day 5 for 
immunohistochemistry.  A representative image is shown for each experimental 
condition. 
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Figure 14.  Drug B inhibits CFA-mediated stimulation of PKA expression in the spinal 
trigeminal nucleus.  Drug B was administered on day 3 and 4 post CFA injection and 
upper spinal cord tissue removed on day 5 for immunohistochemistry.  A representative 
image is shown for each experimental condition. 
 
 
 
 
 
 
 
Condition Relative Intensity of PKA Staining (Mean +/- 
SEM) 
Saline + Vitamin E 1.00 ± 0.10 
Saline + Drug B 1.14 ± 0.17 
CFA + Vitamin E 2.31 ± 0.26 * 
CFA + Drug B 1.16 ± 0.11 # 
  
 * = p < 0.01 when compared to Saline + Vitamin E 
 # = p < 0.01 when compared to CFA 
Saline + Vitamin E Saline + Drug B 
CFA + Vitamin E CFA + Drug B 
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Figure 15.  Topiramate does not inhibit CFA-mediated stimulation of PKA expression in 
the spinal trigeminal nucleus.  Topiramate was administered on day 3 and 4 post CFA 
injection and upper spinal cord tissue removed on day 5 for immunohistochemistry.  A 
representative image is shown for each experimental condition. 
 
 
Condition Relative Intensity of PKA Staining (Mean +/- SEM) 
Naïve 1.00 ± 0.07 
Saline + DMSO 1.03 ± 0.09 
Saline + Topiramate 0.94 ± 0.11 
CFA + DMSO 1.79 ± 0.13 * 
CFA + Topiramate 1.84 ± 0.14 
  
 * = p < 0.01 when compared to Naïve 
Naive 
Saline + DMSO Saline + Topiramate 
CFA + DMSO CFA + Topiramate 
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DISCUSSION 
 
Effect of Anti-Migraine Drugs on Nociception 
 A main goal of my study was to determine if the novel anti-migraine drugs 
designated as Drug A and Drug B could inhibit ongoing peripheral and central 
sensitization and nociception in an animal model of chronic migraine.  A characteristic 
feature of frequent and chronic migraine is prolonged sensitization of primary and 
secondary sensory trigeminal neurons that provide innervation to most of the head and 
face and facilitate transmission of painful stimuli from the peripheral tissues to the CNS.  
I chose to use the inflammatory chemical mediator CFA, which is a heat-killed 
bacterium, to promote sustained peripheral tissue inflammation and nociception of 
trigeminal neurons.  The physiological and cellular effects of CFA injection into the TMJ 
capsule or masseter muscles of mastication have been well characterized by our 
laboratory as well as other research laboratories (Ambalavanar et al., 2006, Suzuki et al., 
2007, Garrett and Durham, 2009, Cady and Durham, 2010, Cady et al., 2010, Garrett et 
al., 2012, Cady et al., 2014, Romero-Reyes et al., 2015) .  Following CFA injection into 
the capsule or muscle, there is an acute phase of nociception to mechanical stimulation 
that resolves by 48 hours post injection.  However, a more chronic phase of nociception 
returns on day 4 reaching a peak on day 5 and then is sustained for up to 14 days.   The 
prolonged nature of the inflammatory response to CFA is responsible for the 
development of a more persistent state of peripheral and central sensitization of the 
trigeminal neurons associated with increased nociception.  Thus, CFA-mediated changes 
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in the trigeminal nociceptive neurons mimic some aspects of frequent and chronic 
migraine and provides a useful model for studying novel anti-migraine drugs.   
 I found that treatment with Drug A and B on days 3 and 4 post CFA injection 
could significantly inhibit the average number of nocifensive responses to mechanical 
stimulation of the trigeminal neurons on day 5, which is the time of peak sensitization.  In 
my model, CFA was injected into both TMJ capsules and nocifensive withdrawal 
responses to mechanical stimulation monitored 2 hours post injection and then on days 3, 
5, 7, 10, and 14 post injection.  CFA caused a rapid increase in nocifensive behavioral 
response within 2 hours following injection that was sustained throughout the 14 day 
duration of my experiment.  The 2 hour time point was used to determine whether the 
CFA injections were performed correctly since the acute nocifensive response is known 
to be followed by a more prolonged inflammatory and nociceptive response in the 
trigeminal system.  While Drug A was able to repress CFA-mediated nocifensive 
response only on day 5, pretreatment with Drug B, which is a structural isomer of Drug 
A, significantly inhibited the number of withdrawals on days 7 and 10.  These data 
support the notion that the structural change to Drug B extended the therapeutic window 
of this drug beyond that of the parent compound and thus may be more beneficial in the 
treatment of frequent and chronic migraine.  I can only speculate on why Drug B has a 
greater duration of efficacy.  It is possible that the modification of the parent Drug A 
compound increases the half-life of Drug B in the animal or it produces a more stable 
secondary metabolite that prolongs its ability to inhibit trigeminal nociception.  However, 
it should be noted that neither of the drugs completely abort the nocifensive response 
since even in animals receiving Drug B exhibited an increase in the number of 
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nocifensive withdrawals on day 14 post CFA injection.  A likely explanation for the 
prolonged CFA response on day 14 is that there is still ongoing inflammation in the TMJ 
capsule that is sustaining both peripheral and central sensitization.  Importantly, I did not 
observe any negative side effects such as changes in grooming or feeding behaviors in 
animals receiving a single dose of either drug.  Results from my study are suggestive that 
Drug A and Drug B would need to be administered on a regular basis to achieve full 
inhibition of nociception caused by trigeminal sensory neuron activation.   
 A major goal of my study was to compare the therapeutic benefit of Drug A and 
Drug B to currently used medications for the treatment of frequent migraine attacks.  
Towards this end, I chose to study the effect of the drug Topiramate, which is approved 
by the Federal Drug Administration, in my model of sustained trigeminal sensitization 
and activation.  However in contrast to Drug A and Drug B, Topiramate administered on 
a daily bases via intraperitoneal injection did not inhibit the nocifensive response to 
mechanical stimulation at any of the time periods.  The choice of daily administration is 
based on the recommended clinical dosing regimen for Topiramate in which it is taken 
daily to reduce the frequency, duration, and severity of frequent episodic migraine attacks 
(Brandes et al., 2004, Diener et al., 2007, Cady et al., 2012b).  Given that Topiramate is 
proposed to function by reducing neuronal hyperexcitability and release of inflammatory 
molecules (Silberstein, 2006, Bolcskei et al., 2009), my findings are somewhat 
surprising.  Although Topiramate is approved for the treatment of frequent migraine, a 
significant number of patients report no benefit from taking this drug and many 
discontinue to use if for managing their migraine attacks because of the sometimes severe 
negative side effects.  My findings are in contrast to findings from a previous study that 
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Topiramate administered on a daily basis reduced mechanical sensitivity and shortened 
the period of allodynia (nociception in response to a non-painful stimulus) in rats 
(Wieczorkiewicz-Plaza et al., 2004).  In their study, Topiramate (50 mg/kg, i.p.) 
administered daily diminished mechanical sensitivity and shortened the period of 
allodynia and reached statistical significance on the 4th day.  However, it should be noted 
that their model differs in several important ways from my model.  For example, their 
model did not attempt to mimic the pathological features of migraine since they were 
using a neuropathic pain model caused by nerve injury to the sciatic nerve (not the 
trigeminal nerve).  Additionally, they were studying changes in dorsal root ganglion 
nociceptive neurons by investigating withdrawal responses to mechanical stimulation of 
the hind paw.  Furthermore, whereas I used Topiramate as a prophylactic drug and 
administered it daily on days 1-4 (before the “chronic” period), the previous study 
administered Topiramate daily for the duration of their experiment (administered daily – 
1 hr prior to each test).    
 In addition to Topiramate, I also wanted to study the effect of an opioid in my 
model since opioids are known to inhibit nociception caused by inflammation in 
peripheral tissues (Watkins et al., 2005, Kreek et al., 2012, Doehring et al., 2013, Saper 
and Da Silva, 2013).  As reported in a published study from the Durham laboratory 
(Garrett et al., 2012), the opioid drug buprenorphine hydrochloride injected 
subcutaneously in the hindquarter at a final concentration of 0.05 mg/kg one hour prior to 
mechanical testing was shown to significantly inhibit the number of nocifensive 
withdrawals.  Opioid analgesics such as buprenorphine are known to suppress pain by 
blocking pain transmission via sensory neurons from peripheral tissues to the central 
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nervous system and activating neurons in the descending pain inhibition pathway.  In 
addition, drugs that target opioid receptors are commonly used by emergency room 
doctors as an anti-migraine therapy.  I found that administration of buprenorphine 30 
minutes prior to behavioral testing was able to completely abolish the CFA-mediated 
nocifensive response on days 3 and 4. However the inhibitory effect of buprenorphine 
was transient since 24 hours after administration the number of nocifensive responses 
was equivalent to the CFA injected animals and remained that way throughout the 
remainder of the study (day 14).   Thus, buprenorphine is only beneficial in relieving 
nociception temporarily.  This finding is not too surprising given that opioids are not 
known to decrease peripheral inflammation or ongoing peripheral sensitization of 
nociceptors but rather transiently inhibit central pain processing mechanisms (Baron, 
2009, Okada-Ogawa et al., 2009).  Hence, opioids should only be used as a last resort 
treatment option since there is no resolution of the underlying inflammatory process and 
thus, the associated nociceptive response will return once the drug affects have 
diminished.  
     
Regulation of PKA in Trigeminal Ganglion and Upper Spinal Cord Tissue 
 To investigate cellular events that are likely involved in the development of 
peripheral and central sensitization, I chose to focus on changes in the expression of the 
signaling protein PKA in trigeminal ganglia and upper spinal cord tissue containing the 
STN.  Elevated levels of PKA are implicated in the initiation and maintenance of 
peripheral and central sensitization (Aley and Levine, 1999, Hu et al., 2003, Hucho and 
Levine, 2007, Seybold, 2009).  Similar to previous studies, I found that CFA injection 
into the TMJ capsule, which is innervated primarily by V3 neurons, caused a significant 
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increase in level of PKA expression in trigeminal ganglion neurons throughout the 
ganglion (V1, V2, and V3) when compared to naïve untreated and vehicle only treated 
animals.  Our laboratory has previously described this type of cross-excitation within the 
trigeminal ganglion that likely facilitates sensitization of other neurons that likely 
functions to expand the receptive field following tissue injury (Thalakoti et al., 2007, 
Durham and Garrett, 2010).  Treatment with Drug A or Drug B on days 3 and 4 post CFA 
injection into the TMJ capsule greatly inhibited PKA expression in neurons on day 5, the 
time of peak nocifensive response to CFA.  In contrast, treatment with the dilution 
vehicle did not cause repression of CFA-mediated increases in PKA staining intensity or 
number of positive cells.  In agreement with my behavioral results, administration of 
Topiramate did not inhibit elevated levels of PKA in response to CFA.  The modulatory 
effects of PKA are thought to involve activation of pathways and transcription factors 
that regulate the expression and activity level of ion channels and receptors in nociceptive 
neurons and increase expression of pro-inflammatory molecules in both neurons and glial 
cells (Seybold, 2009).  My findings provide evidence that the inhibitory effect of Drug A 
and Drug B are likely mediated, at least in part, to repression of PKA levels in trigeminal 
primary nociceptive neurons.  Furthermore, these results may help to explain why I 
observed that Drug A and Drug B could inhibit nocifensive withdrawal responses to 
mechanical stimulation but not Topiramate.  
I also found that CFA injection into the TMJ capsule caused a large increase in 
the level of PKA expression in the spinal trigeminal nucleus when compared to levels in 
naïve unstimulated animals and animals receiving saline (control for CFA injection) or 
DMSO (control for drugs).  Within the spinal cord, activation of the PKA pathway has 
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been shown to lead to central sensitization of second order nociceptive neurons and can 
promote bidirectional sensitization of primary nociceptors (Kohno et al., 2008, Cady et 
al., 2011, Hawkins et al., 2015).  With respect to migraine and TMJ pathology, the PKA 
pathway is thought to play a central role since this signal transduction pathways is 
activated by the neuropeptide CGRP, which is released from primary trigeminal sensory 
neurons in response to peripheral tissue injury.  The cellular effects of CGRP are likely to 
be mediated by both neurons and glial cells since the CGRP receptor is expressed on 
neuronal cell bodies, astrocytes, and microglia (Durham, 2008, Durham and Vause, 
2010).  Following binding of CGRP to its receptor, there is a large increase in the 
secondary messenger cAMP that causes activation of PKA, which can promote cellular 
changes via phosphorylation of proteins that function to regulate the excitability state of 
neurons and glial and the synthesis and release of pro-inflammatory molecules that 
sustain central sensitization.  In my study, Drug A and Drug B were found to repress the 
stimulatory effect of CFA on PKA expression in the spinal trigeminal nucleus when 
compared to DMSO treated animals.  In contrast, treatment with Topiramate did not 
inhibit the CFA-induced change in PKA.  These findings are in agreement with both my 
behavioral data and results observed in the trigeminal ganglion and support the notion 
that Drug A and Drug B can transiently inhibit nociception by repressing CFA 
stimulation of the PKA pathway and promotion of central sensitization.   
 
Summary and Future Directions 
 Based on my findings, I propose that both Drug A and Drug B would be 
beneficial as a therapeutic agent for frequent episodic and chronic migraine by inhibiting 
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sustained peripheral and central sensitization of trigeminal nerves.  The mechanism of 
action of Drug A and Drug B is unique compared to Topiramate, a drug approved as a 
therapy for frequent episodic migraine.  The cellular data (inhibition of PKA in ganglia 
and spinal cord) supports the notion that Drug A and Drug B inhibition of nocifensive 
signaling involves suppressing the sustained development of peripheral and central 
sensitization, which are key physiological events associated with frequent episodic and 
chronic migraine.   While both Drug A and Drug B were shown to be effective in my 
model of prolonged trigeminal nerve sensitization, the longer repressive effect of Drug B 
supports its further characterization as a promising anti-migraine therapy for frequent and 
chronic migraine.  Based on my behavioral data that demonstrated transient inhibition of 
mechanical sensitivity, I propose that Drug A and Drug B would need to be administered 
on a daily basis to provide a therapeutic benefit to patients experiencing either frequent 
episodic or chronic migraine.  Within the migraine community, preventing the 
progression of episodic to chronic migraine needs to be considered a top priority in the 
management of migraine patients since patients without effective acute therapy are at 
greater risk of developing CM (Cady et al., 2004).  Given that Topiramate is the only 
drug with FDA approval for the treatment of frequent episodic migraine and BOTOX 
(onabotulinumtoxin type A) is the only drug approved for the treatment of chronic 
migraine, there remains a great need for the development of safer and more effective anti-
migraine medications.   
 There are many unanswered questions with respect to the mechanism of action of 
Drug A and Drug B that would be of interest to investigate.  Initially, it would be 
important to determine the effect of different doses and time of administration on efficacy 
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and safety.  Could these drugs be used as preventative (prophylaxis) therapy in addition 
to be utilized as abortive drugs?  I found that these drugs could inhibit PKA expression 
but it is likely that other signaling pathways known to promote peripheral and central 
sensitization such as the mitogen-activated protein kinase or MAP kinase pathway would 
be a cellular target.  Given the hydrophobic nature of the drugs, it is likely that their 
inhibitory effects would extend beyond the trigeminal system so it would be important to 
determine if they block nociception in tissues innervated by the dorsal root ganglion (e.g., 
knee, ankle, wrist, shoulder, and hip joints).  Also, it is possible that these drugs may 
influence nociception at higher levels within the brain such as the thalamus.  If higher 
doses of the drugs were tested, it would be essential to investigate changes in cognitive 
ability to clearly differentiate the mechanism of action of these drugs when compared to 
Topiramate, which is known to cause cognitive impairment.  Our laboratory has been 
developing more clinically relevant animal models that more closely mimic key 
pathophysiological features of episodic and chronic migraine (risk factors and triggers), 
so it would be of interest to know how Drug A and Drug B perform in these novel 
models.   
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